Colestipol Hydrochloride and Inlyta

• Generic Name: colestipol
• Dosage Forms: n.a.
• Other Brand Names: Colestid, Colestid Flavored

Adjunct to dietary therapy to decrease elevated serum total and LDL-cholesterol concentrations in the management of primary hypercholesterolemia in patients who do not respond adequately to diet.

Generally has no clinically relevant effect on serum triglyceride concentrations, but may increase triglyceride concentrations in some patients. (See Hypertriglyceridemia under Cautions.) Do not use in patients with primary dysbetalipoproteinemia (Fredrickson type III).

As effective as cholestyramine in lowering serum cholesterol concentrations. Select bile acid sequestrant based on patient tolerance, including palatability and taste preference, and cost.

ACC/AHA cholesterol management guideline states that nonstatin drugs (e.g., bile acid sequestrants) do not provide acceptable atherosclerotic cardiovascular disease (ASCVD) risk reduction benefits compared to their potential for adverse effects in the routine prevention of ASCVD. May be useful as adjuncts to statin therapy in high-risk patients (e.g., patients with ASCVD, LDL-cholesterol concentrations ≥190 mg/dL, or diabetes mellitus) who have a less-than-anticipated response to statins, are unable to tolerate even a less-than-recommended intensity of a statin, or are completely intolerant to statin therapy. Select nonstatin drug based on favorable benefit-risk ratio (i.e., demonstrated benefit of ASCVD risk reduction outweighs risks of adverse effects and drug interactions) and patient preferences.

• Generic Name: axitinib
• Dosage Forms: tablet, film coated
• Other Brand Names: Inlyta

Inlyta (axitinib) is a prescription medicine that interferes with the growth of some cancer cells.

Inlyta is used to treat advanced kidney cancer (advanced renal cell carcinoma) when one prior drug treatment regimen for the kidney cancer has not worked.

It is not known if Inlyta is safe and effective in children.